US20040254635A1 - Expandable medical device for delivery of beneficial agent - Google Patents

Abstract

An expandable medical device has a plurality of elongated struts joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. At least one of the plurality of struts includes at least one opening extending at least partially through a thickness of the strut. A beneficial agent is loaded into the opening within the strut in layers to achieve desired temporal release kinetics of the agent. Alternatively, the beneficial agent is loaded in a shape which is configured to achieve the desired agent delivery profile. A wide variety of delivery profiles can be achieved including zero order, pulsatile, increasing, decrease, sinusoidal, and other delivery profiles.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
• This application is a continuation-in-part of pending U.S. application Ser. No. 10/668,430, filed Sep. 22, 2003, which claims priority to U.S. Provisional Application Ser. No. 60/412,489, filed Sep. 20, 2002. This application is also a continuation-in-part of pending U.S. application Ser. No. 10/253,020, filed on Sep. 23, 2002, which is a continuation-in-part of U.S. application Ser. No. 09/948,989, filed on Sep. 7, 2001, which claims priority to U.S. Provisional Application Ser. No. 60/314,259, filed Aug. 20, 2001 and which is a continuation-in-part of U.S. application Ser. No. 09/688,092, filed Oct. 16, 2000 which is a continuation-in-part of U.S. application Ser. No. 09/183,555, filed Oct. 29, 1998, now U.S. Pat. No. 6,241,762, which claims priority to U.S. Provisional Application Ser. No. 60/079,881, filed Mar. 30, 1998.[0001]
BACKGROUND OF THE INVENTION
• 1. Field of the Invention[0002]
• The present invention relates to tissue-supporting medical devices, and more particularly to expandable, non-removable devices that are implanted within a bodily lumen of a living animal or human to support the organ and maintain patency, and that can deliver a beneficial agent to the intervention site.[0003]
• 2. Summary of the Related Art[0004]
• In the past, permanent or biodegradable devices have been developed for implantation within a body passageway to maintain patency of the passageway. These devices are typically introduced percutaneously, and transported transluminally until positioned at a desired location. These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.[0005]
• Known stent designs include monofilament wire coil stents (U.S. Pat. No. 4,969,458); welded metal cages (U.S. Pat. Nos. 4,733,665 and 4,776,337); and, most prominently, thin-walled metal cylinders with axial slots formed around the circumference (U.S. Pat. Nos. 4,733,665; 4,739,762; and 4,776,337). Known construction materials for use in stents include polymers, organic fabrics and biocompatible metals, such as, stainless steel, gold, silver, tantalum, titanium, and shape memory alloys such as Nitinol.[0006]
• U.S. Pat. Nos. 4,733,665; 4,739,762; and 4,776,337 disclose expandable and deformable interluminal vascular grafts in the form of thin-walled tubular members with axial slots allowing the members to be expanded radially outwardly into contact with a body passageway. After insertion, the tubular members are mechanically expanded beyond their elastic limit and thus permanently fixed within the body. U.S. Pat. No. 5,545,210 discloses a thin-walled tubular stent geometrically similar to those discussed above, but constructed of a nickel-titanium shape memory alloy (“Nitinol”), which can be permanently fixed within the body without exceeding its elastic limit. All of these stents share a critical design property: in each design, the features that undergo permanent deformation during stent expansion are prismatic, i.e., the cross sections of these features remain constant or change very gradually along their entire active length. These prismatic structures are ideally suited to providing large amounts of elastic deformation before permanent deformation commences, which in turn leads to sub-optimal device performance in important properties including stent expansion force, stent recoil, strut element stability, stent securement on delivery catheters, and radiopacity.[0007]
• U.S. Pat. No. 6,241,762, which is incorporated herein by reference in its entirety, discloses a non-prismatic stent design which remedies the above mentioned performance deficiencies of previous stents. In addition, preferred embodiments of this patent provide a stent with large, non-deforming strut and link elements, which can contain holes without compromising the mechanical properties of the strut or link elements, or the device as a whole. Further, these holes may serve as large, protected reservoirs for delivering various beneficial agents to the device implantation site.[0008]
• Of the many problems that may be addressed through stent-based local delivery of beneficial agents, one of the most important is restenosis. Restenosis is a major complication that can arise following vascular interventions such as angioplasty and the implantation of stents. Simply defined, restenosis is a wound healing process that reduces the vessel lumen diameter by extracellular matrix deposition and vascular smooth muscle cell proliferation, and which may ultimately result in renarrowing or even reocclusion of the lumen. Despite the introduction of improved surgical techniques, devices and pharmaceutical agents, the overall restenosis rate is still reported in the range of 25% to 50% within six to twelve months after an angioplasty procedure. To treat this condition, additional revascularization procedures are frequently required, thereby increasing trauma and risk to the patient.[0009]
• Some of the techniques under development to address the problem of restenosis include irradiation of the injury site and the use of conventional stents to deliver a variety of beneficial or pharmaceutical agents to the wall of the traumatized vessel. In the latter case, a conventional stent is frequently surface-coated with a beneficial agent (often a drug-impregnated polymer) and implanted at the angioplasty site. Alternatively, an external drug-impregnated polymer sheath is mounted over the stent and co-deployed in the vessel.[0010]
• While acute outcomes from radiation therapies appeared promising initially, long term beneficial outcomes have been limited to reduction in restenosis occurring within a previously implanted stent, so-called ‘in-stent’ restenosis. Radiation therapies have not been effective for preventing restenosis in de novo lesions. Polymer sheaths that span stent struts have also proven problematic in human clinical trials due to the danger of blocking flow to branch arteries, incomplete apposition of stent struts to arterial walls and other problems. Unacceptably high levels of MACE (Major Adverse Cardiac Events that include death, heart attack, or the need for a repeat angioplasty or coronary artery bypass surgery) have resulted in early termination of clinical trials for sheath covered stents.[0011]
• Conventional stents with surface coatings of various beneficial agents, by contrast, have shown promising early results. U.S. Pat. No. 5,716,981, for example, discloses a stent that is surface-coated with a composition comprising a polymer carrier and paclitaxel (a well-known compound that is commonly used in the treatment of cancerous tumors). The patent offers detailed descriptions of methods for coating stent surfaces, such as spraying and dipping, as well as the desired character of the coating itself: it should “coat the stent smoothly and evenly” and “provide a uniform, predictable, prolonged release of the anti-angiogenic factor.” Surface coatings, however, can provide little actual control over the release kinetics of beneficial agents. These coatings are necessarily very thin, typically 5 to 8 microns deep. The surface area of the stent, by comparison is very large, so that the entire volume of the beneficial agent has a very short diffusion path to discharge into the surrounding tissue.[0012]
• Increasing the thickness of the surface coating has the beneficial effects of improving drug release kinetics including the ability to control drug release and to allow increased drug loading. However, the increased coating thickness results in increased overall thickness of the stent wall. This is undesirable for a number of reasons, including increased trauma to the vessel wall during implantation, reduced flow cross-section of the lumen after implantation, and increased vulnerability of the coating to mechanical failure or damage during expansion and implantation. Coating thickness is one of several factors that affect the release kinetics of the beneficial agent, and limitations on thickness thereby limit the range of release rates, durations, and the like that can be achieved.[0013]
• In addition to sub-optimal release profiles, there are further problems with surface coated stents. The fixed matrix polymer carriers frequently used in the device coatings typically retain approximately 30% of the beneficial agent in the coating indefinitely. Since these beneficial agents are frequently highly cytotoxic, sub-acute and chronic problems such as chronic inflammation, late thrombosis, and late or incomplete healing of the vessel wall may occur. Additionally, the carrier polymers themselves are often highly inflammatory to the tissue of the vessel wall. On the other hand, use of bio-degradable polymer carriers on stent surfaces can result in the creation of “virtual spaces” or voids between the stent and tissue of the vessel wall after the polymer carrier has degraded, which permits differential motion between the stent and adjacent tissue. Resulting problems include micro-abrasion and inflammation, stent drift, and failure to re-endothelialize the vessel wall.[0014]
• Another significant problem is that expansion of the stent may stress the overlying polymeric coating causing the coating to plastically deform or even to rupture, which may therefore effect drug release kinetics or have other untoward effects. Further, expansion of such a coated stent in an atherosclerotic blood vessel will place circumferential shear forces on the polymeric coating, which may cause the coating to separate from the underlying stent surface. Such separation may again have untoward effects including embolization of coating fragments causing vascular obstruction.[0015]
SUMMARY OF THE INVENTION
• In view of the drawbacks of the prior art, it would be advantageous to provide a stent capable of delivering a relatively large volume of a beneficial agent to a traumatized site in a vessel while avoiding the numerous problems associated with surface coatings containing beneficial agents, without increasing the effective wall thickness of the stent, and without adversely impacting the mechanical expansion properties of the stent.[0016]
• It would further be advantageous to have such a stent, which also significantly increases the available depth of the beneficial agent reservoir.[0017]
• It would also be advantageous to have methods of loading various beneficial agents or combinations of beneficial agents into these deep reservoirs, which provided control over the temporal release kinetics of the agents.[0018]
• In accordance with one aspect of the invention, a device for the controlled release of one or more drugs comprises an implantable stent, at least two reservoirs in the stent, and a release system contained in each of the at least two reservoirs, wherein the release system comprises one or more drugs for release.[0019]
BRIEF DESCRIPTION OF THE DRAWINGS
• The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:[0020]
• FIG. 1 is a perspective view of a tissue supporting device in accordance with a first preferred embodiment of the present invention;[0021]
• FIG. 2 is an enlarged side view of a portion of the device of FIG. 1;[0022]
• FIG. 3 is an enlarged side view of a tissue supporting device in accordance with a further preferred embodiment of the present invention;[0023]
• FIG. 4 is an enlarged side view of a portion of the stent shown in FIG. 3;[0024]
• FIG. 5 is an enlarged cross section of an opening;[0025]
• FIG. 6 is an enlarged cross section of an opening illustrating beneficial agent loaded into the opening;[0026]
• FIG. 7 is an enlarged cross section of an opening illustrating a beneficial agent loaded into the opening and a thin coating of a beneficial agent;[0027]
• FIG. 8 is an enlarged cross section of an opening illustrating a beneficial agent loaded into the opening and thin coatings of different beneficial agents on different surfaces of the device;[0028]
• FIG. 9 is an enlarged cross section of an opening illustrating a beneficial agent provided in a plurality of layers;[0029]
• FIG. 10 is an enlarged cross section of an opening illustrating a beneficial agent and a barrier layer loaded into the opening in layers;[0030]
• FIG. 11A is an enlarged cross section of an opening illustrating a beneficial agent, a biodegradable carrier, and a barrier layer loaded into the opening in layers;[0031]
• FIG. 11B is a graph of the release kinetics of the device of FIG. 11A;[0032]
• FIG. 12 is an enlarged cross section of an opening illustrating different beneficial agents, carrier, and barrier layers loaded into the opening;[0033]
• FIG. 13 is an enlarged cross section of an opening illustrating a beneficial agent loaded into the opening in layers of different concentrations;[0034]
• FIG. 14 is an enlarged cross section of an opening illustrating a beneficial agent loaded into the opening in layers of microspheres of different sizes;[0035]
• FIG. 15A is an enlarged cross section of a tapered opening illustrating a beneficial agent loaded into the opening;[0036]
• FIG. 15B is an enlarged cross section of the tapered opening of FIG. 15A with the beneficial agent partially degraded;[0037]
• FIG. 15C is a graph of the release kinetics of the device of FIGS. 15A and 15B;[0038]
• FIG. 16A is an enlarged cross section of an opening illustrating a beneficial agent loaded into the opening in a shape configured to achieve a desired agent delivery profile;[0039]
• FIG. 16B is an enlarged cross section of the opening of FIG. 16A with the beneficial agent partially degraded;[0040]
• FIG. 16C is a graph of the release kinetics of the device of FIGS. 16A and 16B;[0041]
• FIG. 17A is an enlarged cross section of an opening illustrating the beneficial agent loaded into the opening and a spherical shape;[0042]
• FIG. 17B is a graph of the release kinetics of the device of FIG. 17A;[0043]
• FIG. 18A is an enlarged cross section of an opening illustrating a plurality of beneficial agent layers and a barrier layer with an opening for achieving a desired agent delivery profile;[0044]
• FIG. 18B is an enlarged cross section of the opening of FIG. 18A with the agent layers beginning to degraded;[0045]
• FIG. 18C is an enlarged cross section of the opening of FIG. 18A with the agent layers further degraded;[0046]
• FIG. 19 is an enlarged cross section of an opening illustrating a plurality of cylindrical beneficial agent layers;[0047]
• FIG. 20 is an isometric view of an expandable tissue supporting device with different beneficial agents in different holes;[0048]
• FIG. 21 is an isometric view of an expandable tissue supporting device with different beneficial agents in alternating holes; and[0049]
• FIG. 22 is an enlarged side view of a portion of an expandable tissue supporting device with beneficial agent openings in the bridging elements.[0050]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
• Referring to FIGS. 1 and 2, a tissue supporting device in accordance with one preferred embodiment of the present invention is shown generally by[0051]reference numeral10. Thetissue supporting device10 includes a plurality ofcylindrical tubes12 connected by S-shapedbridging elements14. The bridgingelements14 allow the tissue supporting device to bend axially when passing through the tortuous path of the vasculature to the deployment site and allow the device to bend when necessary to match the curvature of a vessel wall to be supported. Each of thecylindrical tubes12 has a plurality ofaxial slots16 extending from an end surface of the cylindrical tube toward an opposite end surface.
• Formed between the[0052]slots16 is a network ofaxial struts18 and links22. Thestruts18 andlinks22 are provided with openings for receiving and delivering a beneficial agent. As will be described below with respect to FIGS. 9-17, the beneficial agent is loaded into the openings in layers or other configurations which provide control over the temporal release kinetics of the agent.
• Each[0053]individual strut18 is preferably linked to the rest of the structure through a pair of reducedsections20, one at each end, which act as stress/strain concentration features. The reducedsections20 of the struts function as hinges in the cylindrical structure. Since the stress/strain concentration features are designed to operate into the plastic deformation range of generally ductile materials, they are referred to as ductile hinges20. The ductile hinges20 are described in further detail in U.S. Pat. No. 6,241,762, which has been incorporated herein by reference.
• With reference to the drawings and the discussion, the width of any feature is defined as its dimension in the circumferential direction of the cylinder. The length of any feature is defined as its dimension in the axial direction of the cylinder. The thickness of any feature is defined as the wall thickness of the cylinder.[0054]
• The presence of the ductile hinges[0055]20 allows all of the remaining features in the tissue supporting device to be increased in width or the circumferentially oriented component of their respective rectangular moments of inertia—thus greatly increasing the strength and rigidity of these features. The net result is that elastic, and then plastic deformation commence and propagate in the ductile hinges20 before other structural elements of the device undergo any significant elastic deformation. The force required to expand thetissue supporting device10 becomes a function of the geometry of the ductile hinges20, rather than the device structure as a whole, and arbitrarily small expansion forces can be specified by changing hinge geometry for virtually any material wall thickness. The ability to increase the width and thickness of thestruts18 andlinks22 provides additional area and depth for the beneficial agent receiving openings.
• In the embodiment of FIGS. 1 and 2, it is desirable to increase the width of the individual struts[0056]18 between the ductile hinges20 to the maximum width that is geometrically possible for a given diameter and a given number of struts arrayed around that diameter. The only geometric limitation on strut width is the minimum practical width of theslots16 which is about 0.002 inches (0.0508 mm) for laser machining. Lateral stiffness of thestruts18 increases as the cube of strut width, so that relatively small increases in strut width significantly increase strut stiffness. The net result of inserting ductile hinges20 and increasing strut width is that thestruts18 no longer act as flexible leaf springs, but act as essentially rigid beams between the ductile hinges. All radial expansion or compression of the cylindricaltissue supporting device10 is accommodated by mechanical strain in the hinge features20, and yield in the hinge commences at very small overall radial expansion or compression.
• The[0057]ductile hinge20 illustrated in FIGS. 1 and 2 is exemplary of a preferred structure that will function as a stress/strain concentrator. Many other stress/strain concentrator configurations may also be used as the ductile hinges in the present invention, as shown and described by way of example in U.S. Pat. No. 6,241,762. The geometric details of the stress/strain concentration features or ductile hinges20 can be varied greatly to tailor the exact mechanical expansion properties to those required in a specific application.
• Although a tissue supporting device configuration has been illustrated in FIG. 1 which includes ductile hinges, it should be understood that the beneficial agent may be contained in openings in stents having a variety of designs including the designs illustrated in U.S. Provisional Patent Application Ser. No. 60/314,360, filed on Aug. 20, 2001 and U.S. patent application Ser. No. 09/948,987, filed on Sep. 7, 2001 (Attorney Docket No. 032304-033), which are incorporated herein by reference. The present invention incorporating beneficial agent openings may also be used with other known stent designs.[0058]
• As shown in FIGS. 1-4, at least one and more preferably a series of[0059]openings24 are formed by laser drilling or any other means known to one skilled in the art at intervals along the neutral axis of thestruts18. Similarly, at least one and preferably a series ofopenings26 are formed at selected locations in thelinks22. Although the use ofopenings24 and26 in both thestruts18 andlinks22 is preferred, it should be clear to one skilled in the art that openings could be formed in only one of the struts and links. Openings may also be formed in thebridging elements14. In the embodiment of FIGS. 1 and 2, theopenings24,26 are circular in nature and form cylindrical holes extending through the width of thetissue supporting device10. It should be apparent to one skilled in the art, however, that openings of any geometrical shape or configuration could of course be used without departing from the scope of the present invention. In addition, openings having a depth less than the thickness of the device may also be used.
• The behavior of the[0060]struts18 in bending is analogous to the behavior of an I-beam or truss. Theouter edge elements32 of thestruts18, shown in FIG. 2, correspond to the I-beam flange and carry the tensile and compressive stresses, whereas theinner elements34 of thestruts18 correspond to the web of an I-beam which carries the shear and helps to prevent buckling and wrinkling of the faces. Since most of the bending load is carried by theouter edge elements32 of thestruts18, a concentration of as much material as possible away from the neutral axis results in the most efficient sections for resisting strut flexure. As a result, material can be judiciously removed along the axis of the strut so as to formopenings24,26 without adversely impacting the strength and rigidity of the strut. Since thestruts18 andlinks22 thus formed remain essentially rigid during stent expansion, theopenings24,26 are also non-deforming.
• The[0061]openings24,26 in thestruts18 may promote the healing of the intervention site by promoting regrowth of the endothelial cells. By providing theopenings24,26 in the struts,18, the cross section of the strut is effectively reduced without decreasing the strength and integrity of the strut, as described above. As a result, the overall distance across which endothelial cell regrowth must occur is also reduced to approximately 0.0025-0.0035 inches, which is approximately one-half of the thickness of a conventional stent. It is further believed that during insertion of the expandable medical device, cells from the endothelial layer may be scraped from the inner wall of the vessel by theopenings24,26 and remain therein after implantation. The presence of such endothelial cells would thus provide a basis for the healing of the vessel wall.
• The[0062]openings24,26 are loaded with an agent, most preferably a beneficial agent, for delivery to the vessel wall which thetissue supporting device10 is supporting.
• The terms “agent” and “beneficial agent” as used herein are intended to have their broadest possible interpretation and are used to include any therapeutic agent or drug, as well as inactive agents such as barrier layers or carrier layers. The terms “drug” and “therapeutic agent” are used interchangeably to refer to any therapeutically active substance that is delivered to a bodily conduit of a living being to produce a desired, usually beneficial, effect. The present invention is particularly well suited for the delivery of antiproliferatives (anti-restenosis agents) such as paclitaxel and rapamycin for example, and antithrombins such as heparin, for example.[0063]
• Additional uses, however, include therapeutic agents in all the major therapeutic areas including, but not limited to: anti-infectives such as antibiotics and antiviral agents; analgesics, including fentanyl, sufentanil, buprenorphine and analgesic combinations; anesthetics; anorexics; antiarthritics; antiasthmatic agents such as terbutaline; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antimotion sickness preparations such as scopolamine and ondansetron; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics, including gastrointestinal and urinary; anticholinergics; sympathomimetrics; xanthine derivatives; cardiovascular preparations, including calcium channel blockers such as nifedipine; beta blockers; beta-agonists such as dobutamine and ritodrine; antiarrythmics; antihypertensives such as atenolol; ACE inhibitors such as ranitidine; diuretics; vasodilators, including general, coronary, peripheral, and cerebral; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones such as parathyroid hormone; hypnotics; immunosuppressants; muscle relaxants; parasympatholytics; parasympathomimetrics; prostaglandins; proteins; peptides; psychostimulants; sedatives; and tranquilizers.[0064]
• The beneficial agents used in the present invention include classical small molecular weight therapeutic agents commonly referred to as drugs including all classes of action as exemplified by, but not limited to: antiproliferatives, antithrombins, antiplatelet, antilipid, anti-inflammatory, angiogenic, anti-angiogenic, vitamins, ACE inhibitors, vasoactive substances, antimitotics, metello-proteinase inhibitors, NO donors, estradiols, anti-sclerosing agents, alone or in combination. Beneficial agent also includes larger molecular weight substances with drug like effects on target tissue sometimes called biologic agents including but not limited to: peptides, lipids, protein drugs, enzymes, oligonucleotides, ribozymes, genetic material, prions, virus, bacteria, and eucaryotic cells such as endothelial cells, monocyte/macrophages or vascular smooth muscle cells to name but a few examples. The therapeutic agent may also be a pro-drug, which metabolizes into the desired drug when administered to a host. Other beneficial agents may include but not be limited to physical agents such as microcapsules, microspheres, microbubbles, liposomes, niosomes, radioactive isotopes, emulsions, dispersions, or agents activated by some other form of energy such as light or ultrasonic energy, or by other circulating molecules that can be systemically administered.[0065]
• The embodiment of the invention shown in FIGS. 1 and 2 can be further refined by using Finite Element Analysis and other techniques to optimize the deployment of the beneficial agent within the openings of the struts and links. Basically, the shape and location of the[0066]openings24,26 can be modified to maximize the volume of the voids while preserving the relatively high strength and rigidity of thestruts18 with respect to the ductile hinges20.
• FIG. 3 illustrates a further preferred embodiment of the present invention, wherein like reference numerals have been used to indicate like components. The[0067]tissue supporting device100 includes a plurality ofcylindrical tubes12 connected by S-shapedbridging elements14. Each of thecylindrical tubes12 has a plurality ofaxial slots16 extending from an end surface of the cylindrical tube toward an opposite end surface. Formed between theslots16 is a network ofaxial struts18 and links22. Eachindividual strut18 is linked to the rest of the structure through a pair of ductile hinges20, one at each end, which act as stress/strain concentration features. Each of the ductile hinges20 is formed between anarc surface28 and aconcave notch surface29.
• At intervals along the neutral axis of the[0068]struts18, at least one and more preferably a series ofopenings24′ are formed by laser drilling or any other means known to one skilled in the art. Similarly, at least one and preferably a series ofopenings26′ are formed at selected locations in thelinks22. Although the use ofopenings24′,26′ in both thestruts18 andlinks22 is preferred, it should be clear to one skilled in the art that openings could be formed in only one of the struts and links. In the illustrated embodiment, theopenings24′ in thestruts18 are generally rectangular whereas theopenings26′ in thelinks22 are polygonal. It should be apparent to one skilled in the art, however, that openings of any geometrical shape or configuration could of course be used, and that the shape ofopenings24,24′ may be the same or different from the shape ofopenings26,26′, without departing from the scope of the present invention. As described in detail above, theopenings24′,26′ may be loaded with an agent, most preferably a beneficial agent, for delivery to the vessel in which thetissue support device100 is deployed. Although theopenings24′,26′ are preferably through openings, they may also be recesses extending only partially through the thickness of the struts and links.
• The relatively large, protected[0069]openings24,24′,26,26′, as described above, make the expandable medical device of the present invention particularly suitable for delivering agents having more esoteric larger molecules or genetic or cellular agents, such as, for example, protein drugs, enzymes, antibodies, antisense oligonucleotides, ribozymes, gene/vector constructs, and cells (including but not limited to cultures of a patient's own endothelial cells). Many of these types of agents are biodegradable or fragile, have a very short or no shelf life, must be prepared at the time of use, or cannot be pre-loaded into delivery devices such as stents during the manufacture thereof for some other reason. The large through-openings in the expandable device of the present invention form protected areas or receptors to facilitate the loading of such an agent either at the time of use or prior to use, and to protect the agent from abrasion and extrusion during delivery and implantation.
• The volume of beneficial agent that can be delivered using through openings is about 3 to 10 times greater than the volume of a 5 micron coating covering a stent with the same stent/vessel wall coverage ratio. This much larger beneficial agent capacity provides several advantages. The larger capacity can be used to deliver multi-drug combinations, each with independent release profiles, for improved efficacy. Also, larger capacity can be used to provide larger quantities of less aggressive drugs and to achieve clinical efficacy without the undesirable side-effects of more potent drugs, such as retarded healing of the endothelial layer.[0070]
• Through openings also decrease the surface area of the beneficial agent bearing compounds to which the vessel wall surface is exposed. For typical devices with beneficial agent openings, this exposure decreases by a factors ranging from about 6:1 to 8:1, by comparison with surface coated stents. This dramatically reduces the exposure of vessel wall tissue to polymer carriers and other agents that can cause inflammation, while simultaneously increasing the quantity of beneficial agent delivered, and improving control of release kinetics.[0071]
• FIG. 4 shows an enlarged view of one of the[0072]struts18 ofdevice100 disposed between a pair of ductile hinges20 having a plurality ofopenings24′. FIG. 5 illustrates a cross section of one of theopenings24′ shown in FIG. 4. FIG. 6 illustrates the same cross section when abeneficial agent36 has been loaded into theopening24′ of thestrut18. Optionally, after loading theopening24′ and/or theopening26′ with abeneficial agent36, the entire exterior surface of the stent can be coated with a thin layer of abeneficial agent38, which may be the same as or different from thebeneficial agent36, as schematically shown in FIG. 7. Still further, another variation of the present invention would coat the outwardly facing surfaces of the stent with a firstbeneficial agent38 while coating the inwardly facing surfaces of the stent with a differentbeneficial agent39, as illustrated in FIG. 8. The inwardly facing surface of the stent would be defined as at least the surface of the stent which, after expansion, forms the inner passage of the vessel. The outwardly facing surface of the stent would be defined as at least the surface of the stent which, after expansion, is in contact with and directly supports the inner wall of the vessel. Thebeneficial agent39 coated on the inner surfaces may be a barrier layer which prevents thebeneficial agent36 from passing into the lumen of the blood vessel and being washed away in the blood stream.
• FIG. 9 shows a cross section of an[0073]opening24 in which one or more beneficial agents have been loaded into theopening24 indiscrete layers50. One method of creating such layers is to deliver a solution comprising beneficial agent, polymer carrier, and a solvent into the opening and evaporating the solvent to create a thin solid layer of beneficial agent in the carrier. Other methods of delivering the beneficial agent can also be used to create layers. According to another method for creating layers, a beneficial agent may be loaded into the openings alone if the agent is structurally viable without the need for a carrier. The process can then be repeated until each opening is partially or entirely filled.
• In a typical embodiment, the total depth of the[0074]opening24 is about 125 to about 140 microns, and the typical layer thickness would be about 2 to about 50 microns, preferably about 12 microns. Each typical layer is thus individually about twice as thick as the typical coating applied to surface-coated stents. There would be at least two and preferably about ten to twelve such layers in a typical opening, with a total beneficial agent thickness about 25 to 28 times greater than a typical surface coating. According to one preferred embodiment of the present invention, the openings have an area of at least 5×10⁻⁶square inches, and preferably at least 7×10⁻⁶square inches.
• Since each layer is created independently, individual chemical compositions and pharmacokinetic properties can be imparted to each layer. Numerous useful arrangements of such layers can be formed, some of which will be described below. Each of the layers may include one or more agents in the same or different proportions from layer to layer. The layers may be solid, porous, or filled with other drugs or excipients.[0075]
• FIG. 9 shows the simplest arrangement of layers including[0076]identical layers50 that together form a uniform, homogeneous distribution of beneficial agent. If the carrier polymer were comprised of a biodegradable material, then erosion of the beneficial agent containing carrier would occur on both faces of the opening at the same time, and beneficial agent would be released at an approximately linear rate over time corresponding to the erosion rate of the carrier. This linear or constant release rate is referred to as a zero order delivery profile. Use of biodegradable carriers in combination with through openings is especially useful, to guarantee 100% discharge of the beneficial agent within a desired time without creating virtual spaces or voids between the radially outermost surface of the stent and tissue of the vessel wall. When the biodegradable material in the through openings is removed, the openings may provide a communication between the strut-covered vessel wall and the blood stream. Such communication may accelerate vessel healing and allow the ingrowth of cells and extracellular components that more thoroughly lock the stent in contact with the vessel wall. Alternatively, some through-openings may be loaded with beneficial agent while others are left unloaded. The unloaded holes could provide an immediate nidus for the ingrowth of cells and extracellular components to lock the stent into place, while loaded openings dispense the beneficial agent.
• The advantage of complete erosion using the through openings over surface coated stents opens up new possibilities for stent-based therapies. In the treatment of cardiac arrhythmias, such as atrial fibrillation both sustained and paroxysmal, sustained ventricular tachycardia, super ventricular tachycardia including reentrant and ectopic, and sinus tachycardia, a number of techniques under development attempt to ablate tissue in the pulmonary veins or some other critical location using various energy sources, e.g. microwaves, generally referred to as radio-frequency ablation, to create a barrier to the propagation of undesired electrical signals in the form of scar tissue. These techniques have proven difficult to control accurately. A stent based therapy using through openings, biodegradable carriers, and associated techniques described herein could be used to deliver a chemically ablative agent in a specific, precise pattern to a specific area for treatment of atrial fibrillation, while guaranteeing that none of the inherently cytotoxic ablating agent could be permanently trapped in contact with the tissue of the vessel wall.[0077]
• If, on the other hand, the goal of a particular therapy is to provide a long term effect, beneficial agents located in openings provide an equally dramatic advantage over surface coated devices. In this case, a composition comprising a beneficial agent and a non-biodegradable carrier would be loaded into the through openings, preferably in combination with a diffusion barrier layer as described below. To continue the cardiac arrhythmias example, it might be desirable to introduce a long-term anti-arrhythmic drug near the ostia of the pulmonary veins or some other critical location. The transient diffusion behavior of a beneficial agent through a non-biodegradable carrier matrix can be generally described by Fick's second law:[0078]$\frac{\partial C_x}{\partial t}=\frac{\partial }{\partial x}\left[D\frac{\partial C_x}{\partial x}\right]$

  
• Where C is the concentration of beneficial agent at cross section x, x is either the thickness of a surface coating or depth of a through opening, D is the diffusion coefficient and t is time. The solution of this partial differential equation for a through opening with a barrier layer will have the form of a normalized probability integral or Gaussian Error Function, the argument of which will contain[0079]$\frac{x}{2\sqrt{\mathrm{Dt}}}$

  
• the term[0080]
• To compare the time intervals over which a given level of therapy can be sustained for surface coatings vs. through openings, we can use Fick's Second Law to compare the times required to achieve equal concentrations at the most inward surfaces of the coating and opening respectively, i.e. the values of x and t for which the arguments[0081]$\frac{x_1}{2\sqrt{{\mathrm{Dt}}_1}}=\frac{x_2}{2\sqrt{{\mathrm{Dt}}_2}}\Rightarrow \frac{x_1^2}{x_2^2}=\frac{t_1}{t_2}$

  
• of the Error Function are equal:[0082]
• The ratio of diffusion times to achieve comparable concentrations thus varies as the square of the ratio of depths. A typical opening depth is about 140 microns while a typical coating thickness is about 5 micron; the square of this ratio is 784, meaning that the effective duration of therapy for through openings is potentially almost three orders of magnitude greater for through openings than for surface coatings of the same composition. The inherent non-linearity of such release profiles can in part be compensated for in the case of through openings, but not in thin surface coatings, by varying the beneficial agent concentration of layers in a through opening as described below. It will be recalled that, in addition to this great advantage in beneficial agent delivery duration, through openings are capable of delivering a 3 to 10 times greater quantity of beneficial agent, providing a decisive overall advantage in sustained therapies. The diffusion example above illustrates the general relationship between depth and diffusion time that is characteristic of a wider class of solid state transport mechanisms.[0083]
• Beneficial agent that is released to the radially innermost or inwardly facing surface known as the lumen facing surface of an expanded device may be rapidly carried away from the targeted area, for example by the bloodstream, and thus lost. Up to half of the total agent loaded in such situations may have no therapeutic effect due to being carried away by the bloodstream. This is probably the case for all surface coated stents as well as the through opening device of FIG. 9.[0084]
• FIG. 10 shows a device in which the[0085]first layer52 is loaded into a throughopening24 such that the inner surface of the layer is substantially co-planar with the inwardly facingsurface54 of the cylindrical device. Thefirst layer52 is comprised of a material called a barrier material which blocks or retards biodegradation of subsequent layers in the inwardly facing direction toward the vessel lumen, and/or blocks or retards diffusion of the beneficial agent in that direction. Biodegradation of other layers or beneficial agent diffusion can then proceed only in the direction of the outwardly facingsurface56 of the device, which is in direct contact with the targeted tissue of the vessel wall. Thebarrier layer52 may also function to prevent hydration of inner layers of beneficial agent and thus prevent swelling of the inner layers when such layers are formed of hygroscopic materials. Thebarrier layer52 may further be comprised of a biodegradable material that degrades at a much slower rate than the biodegradable material in the other layers, so that the opening will eventually be entirely cleared. Providing abarrier layer52 in the most inwardly facing surface of a through-opening thus guarantees that the entire load of beneficial agent is delivered to the target area in the vessel wall. It should be noted that providing a barrier layer on the inwardly facing surface of a surface-coated stent without openings does not have the same effect; since the beneficial agent in such a coating cannot migrate through the metal stent to the target area on the outer surface, it simply remains trapped on the inner diameter of the device, again having no therapeutic effect.
• Barrier layers can be used to control beneficial agent release kinetics in more sophisticated ways. A[0086]barrier layer52 with a pre-determined degradation time could be used to deliberately terminate the beneficial agent therapy at a pre-determined time, by exposing the underlying layers to more rapid bio-degradation from both sides. Barrier layers can also be formulated to be activated by a separate, systemically applied agent. Such systemically applied agent could change the porosity of the barrier layer and/or change the rate of bio-degradation of the barrier layer or the bulk beneficial agent carrier. In each case, release of the beneficial agent could be activated by the physician at will by delivery of the systemically applied agent. A further embodiment of physician activated therapy would utilize a beneficial agent encapsulated in micro-bubbles and loaded into device openings. Application of ultrasonic energy from an exterior of the body could be used to collapse the bubbles at a desired time, releasing the beneficial agent to diffuse to the outwardly facing surface of the reservoirs. These activation techniques can be used in conjunction with the release kinetics control techniques described herein to achieve a desired drug release profile that can be activated and/or terminated at selectable points in time.
• FIG. 11A shows an arrangement of layers provided in a through opening in which layers[0087]50 of a beneficial agent in a biodegradable carrier material, are alternated withlayers58 of the biodegradable carrier material alone, with no active agent loaded, and abarrier layer52 is provided at the inwardly facing surface. As shown in the release kinetics plot of FIG. 11B, such an arrangement releases beneficial agent in three programmable bursts or waves achieving a stepped or pulsatile delivery profile. The use of carrier material layers without active agent creates the potential for synchronization of drug release with cellular biochemical processes for enhanced efficacy.
• Alternatively, different layers could be comprised of different beneficial agents altogether, creating the ability to release different beneficial agents at different points in time, as shown in FIG. 12. For example, in FIG. 12, a[0088]layer60 of anti-thrombotic agent could be deposited at the inwardly facing surface of the stent, followed by abarrier layer52 and alternating layers ofanti-proliferatives62 andanti-inflamatories64. This configuration could provide an initial release of anti-thrombotic agent into the bloodstream while simultaneously providing a gradual release of anti-proliferatives interspersed with programmed bursts of anti-inflammatory agents to the vessel wall. The configurations of these layers can be designed to achieve the agent delivery bursts at particular points in time coordinated with the body's various natural healing processes.
• A further alternative is illustrated in FIG. 13. Here the concentration of the same beneficial agent is varied from layer to layer, creating the ability to generate release profiles of arbitrary shape. Progressively increasing the concentration of agent in the[0089]layers66 with increasing distance from the outwardly facingsurface56, for example, produces a release profile with a progressively increasing release rate, which would be impossible to produce in a thin surface coating.
• Another general method for controlling beneficial agent release kinetics is to alter the beneficial agent flux by changing the surface area of drug elution sources as a function of time. This follows from Fick's First Law, which states that the instantaneous molecular flux is proportional to surface area, among other factors:[0090]$J=D\frac{\partial C}{\partial x}\Rightarrow \frac{\partial N}{\partial t}=\mathrm{AD}\frac{\partial c}{\partial x}$

  
• Where ∂N/∂t is the number of molecules per unit time, A is the instantaneous drug eluting surface area, D is the diffusivity, and C is the concentration. The drug eluting surface area of a surface coated stent is simply the surface area of the stent itself. Since this area is fixed, this method of controlling release kinetics is not available to surface coated devices. Through openings, however, present several possibilities for varying surface area as a function of time.[0091]
• In the embodiment of FIG. 14, beneficial agent is provided in the[0092]openings24 in the form of microspheres, particles or the like.Individual layers70 can then be created that contain these particles. Further, the particle size can be varied from layer to layer. For a given layer volume, smaller particle sizes increase the total particle surface area in that layer, which has the effect of varying the total surface area of the beneficial agent from layer to layer. Since the flux of drug molecules is proportional to surface area, the total drug flux can be adjusted from layer to layer by changing the particle size, and the net effect is control of release kinetics by varying particle sizes within layers.
• A second general method for varying drug eluting surface area as a function of time is to change the shape or cross-sectional area of the drug-bearing element along the axis of the opening. FIG. 15A shows an[0093]opening70 having a conical shape cut into the material of the stent itself. Theopening70 may then be filled withbeneficial agent72 in layers as described above or in another manner. In this embodiment, abarrier layer74 may be provided on the inwardly facing side of theopening70 to prevent thebeneficial agent72 from passing into the blood stream. In this example, the drug eluting surface area A_twould continuously diminish (from FIG. 15A to FIG. 15B) as the bio-degradable carrier material erodes, yielding the elution pattern of FIG. 15C.
• FIG. 16A shows a simple cylindrical through-opening[0094]80 in which a preformed,inverted cone82 of beneficial agent has been inserted. The rest of the throughopening80 is then back-filled with abiodegradable substance84 with a much slower rate of degradation or a non-biodegradable substance, and the inwardly facing opening of the through opening is sealed with abarrier layer86. This technique yields the opposite behavior to the previous example. The drug-eluting surface area A_tcontinuously increases with time between FIGS. 16A and 16B, yielding the elution pattern of FIG. 16C.
• The changing[0095]cross section openings70 of FIG. 15A and the non-biodegradable backfilling techniques of FIG. 16A may be combined with any of the layered agent embodiments of FIGS. 9-14 to achieve desired release profiles. For example, the embodiment of FIG. 15A may use the varying agent concentration layers of FIG. 13 to more accurately tailor a release curve to a desired profile.
• The process of preforming the beneficial agent plug[0096]82 to a special shape, inserting in a through opening, and back-filling with a second material can yield more complex release kinetics as well. FIG. 17A shows a throughopening90 in which a sphericalbeneficial agent plug92 has been inserted. The resulting biodegradation of the sphere, in which the cross sectional surface area varies as a sinusoidal function of depth, produces a flux density which is roughly a sinusoidal function of time, FIG. 17B. Other results are of course possible with other profiles, but none of these more complex behaviors could be generated in a thin, fixed-area surface coating.
• An alternative embodiment of FIGS. 18A-18C use a[0097]barrier layer52′ with anopening96 to achieve the increasing agent release profile of FIG. 16C. As shown in FIG. 18A, theopening24 is provided with aninner barrier layer52 and multiple beneficial agent layers50 as in the embodiment of FIG. 10. An additionalouter barrier layer52′ is provided with asmall hole96 for delivery of the agent to the vessel wall. As shown in FIQS.18B and18C, the beneficialagent containing layers 50 degrade in a hemispherical pattern resulting in increasing surface area for agent delivery over time and thus, an increasing agent release profile.
• FIG. 19 illustrates an alternative embodiment in which an opening in the tissue supporting device is loaded with cylindrical layers of beneficial agent. According to one method of forming the device of FIG. 19, the entire device is coated with[0098]sequential layers100,102,104,106 of beneficial agent. Theinterior surface54 andexterior surface56 of the device are then stripped to remove the beneficial agent on these surfaces leaving the cylindrical layers of beneficial agent in the openings. In this embodiment, a central opening remains after the coating layers have been deposited which allows communication between theouter surface56 andinner surface54 of the tissue supporting device.
• In the embodiment of FIG. 19, the cylindrical layers are eroded sequentially. This can be used for pulsatile delivery of different beneficial agents, delivery of different concentrations of beneficial agents, or delivery of the same agent. As shown in FIG. 19, the ends of the[0099]cylindrical layers100,102,104,106 are exposed. This results in a low level of erosion of the underlying layers during erosion of an exposed layer. Alternatively, the ends of the cylindrical layers may be covered by a barrier layer to prevent this low level continuous erosion. Erosion rates of the cylindrical layers may be further controlled by contouring the surfaces of the layers. For example, a ribbed or star-shaped pattern may be provided on the radially inner layers to provide a uniform surface area or uniform erosion rate between the radially inner layers and the radially outer layers. Contouring of the surfaces of layers may also be used in other embodiments to provide an additional variable for controlling the erosion rates.
• FIG. 20 illustrates a further alternative embodiment of the invention in which different beneficial agents are positioned in different holes of an expandable[0100]medical device300. A first beneficial agent is provided inholes330aat the ends of the device and a second beneficial agent is provided inholes330bat a central portion of the device. The beneficial agent may contain different drugs, the same drugs in different concentrations, or different variations of the same drug. The embodiment of FIG. 20 may be used to provide an expandablemedical device300 with either “hot ends” or “cool ends.”
• Preferably, each end portion of the[0101]device300 which includes theholes330acontaining the first beneficial agent extends at least one hole and up to about 15 holes from the edge. This distance corresponds to about 0.005 to about 0.1 inches from the edge of an unexpanded device. The distance from the edge of thedevice300 which includes the first beneficial agent is preferably about one section, where a section is defined between the bridging elements.
• Different beneficial agents containing different drugs may be disposed in different openings in the stent. This allows the delivery of two or more beneficial agents from a single stent in any desired delivery pattern. Alternatively, different beneficial agents containing the same drug in different concentrations may be disposed in different openings. This allows the drug to be uniformly distributed to the tissue with a non-uniform device structure.[0102]
• The two or more different beneficial agents provided in the devices described herein may contain (1) different drugs; (2) different concentrations of the same drug; (3) the same drug with different release kinetics, i.e., different matrix erosion rates; or (4) different forms of the same drug. Examples of different beneficial agents formulated containing the same drug with different release kinetics may use different carriers to achieve the elution profiles of different shapes. Some examples of different forms of the same drug include forms of a drug having varying hydrophilicity or lipophilicity.[0103]
• In one example of the[0104]device300 of FIG. 20, theholes330aat the ends of the device are loaded with a first beneficial agent comprising a drug with a high lipophilicity whileholes330bat a central portion of the device are loaded with a second beneficial agent comprising the drug with a lower lipophilicity. The first high lipophilicity beneficial agent at the “hot ends” will diffuse more readily into the surrounding tissue reducing the edge effect restenosis.
• The[0105]device300 may have an abrupt transition line at which the beneficial agent changes from a first agent to a second agent. For example, all openings within 0.05 inches of the end of the device may contain the first agent while the remaining openings contain the second agent. Alternatively, the device may have a gradual transition between the first agent and the second agent. For example, a concentration of the drug in the openings can progressively increase (or decrease) toward the ends of the device. In another example, an amount of a first drug in the openings increases while an amount of a second drug in the openings decreases moving toward the ends of the device.
• FIG. 21 illustrates a further alternative embodiment of an expandable[0106]medical device400 in which different beneficial agents are positioned indifferent openings430a,430bin the device in an alternating or interspersed manner. In this manner, multiple beneficial agents can be delivered to tissue over the entire area or a portion of the area supported by the device. This embodiment will be useful for delivery of multiple beneficial agents where combination of the multiple agents into a single composition for loading in the device is not possible due to interactions or stability problems between the beneficial agents.
• In addition to the use of different beneficial agents in different openings to achieve different drug concentrations at different defined areas of tissue, the loading of different beneficial agents in different openings may be used to provide a more even spatial distribution of the beneficial agent delivered in instances where the expandable medical device has a non-uniform distribution of openings in the expanded configuration.[0107]
• For example, in many of the known expandable devices and for the device illustrated in FIG. 22 the coverage of the[0108]device500 is greater at thecylindrical tube portions512 of the device than at the bridgingelements514. Coverage is defined as the ratio of the device surface area to the area of the lumen in which the device is deployed. When a device with varying coverage is used to deliver a beneficial agent contained in openings in the device, the beneficial agent concentration delivered to the tissue adjacent thecylindrical tube portions512 is greater that the beneficial agent delivered to the tissue adjacent the bridgingelements514. In order to address this longitudinal variation in device structure and other variations in device coverage which lead to uneven beneficial agent delivery concentrations, the concentration of the beneficial agent may be varied in the openings at portions of the device to achieve a more even distribution of the beneficial agent throughout the tissue. In the case of the embodiment of FIG. 22, theopenings530ain thetube portions512 include a beneficial agent with a lower drug concentration than theopenings530bin the bridgingelements514. The uniformity of agent delivery may be achieved in a variety of manners including varying the drug concentration, the opening diameter or shape, the amount of agent in the opening (i.e., the percentage of the opening filed), the matrix material, or the form of the drug.
• In addition to the delivery of different beneficial agents to the mural side of the expandable medical device for treatment of the vessel wall, beneficial agents may be delivered to the lumenal side of the expandable medical device. Drugs which are delivered into the blood stream from the lumenal side of the device can be located at a proximal end of the device or a distal end of the device.[0109]
• The methods for loading different beneficial agents into different openings in an expandable medical device may include known techniques such as dipping and coating and also known piezoelectric micro-jetting techniques. Micro-injection devices may be computer controlled to deliver precise amounts of two or more liquid beneficial agents to precise locations on the expandable medical device in a known manner. For example, a dual agent jetting device may deliver two agents simultaneously or sequentially into the openings. When the beneficial agents are loaded into through openings in the expandable medical device, a lumenal side of the through openings may be blocked during loading by a resilient mandrel allowing the beneficial agents to be delivered in liquid form, such as with a solvent. The beneficial agents may also be loaded by manual injection devices.[0110]
• Therapeutic Layer Formulations[0111]
• The therapeutic agent layers of the present invention are beneficial agents comprised of a matrix and at least one therapeutic agent. The term “matrix” or “biocompatible matrix” are used interchangeably to refer to a medium or material that, upon implantation in a subject, does not elicit a detrimental response sufficient to result in the rejection of the matrix. The matrix typically does not provide any therapeutic responses itself, though the matrix may contain or surround a therapeutic agent, a therapeutic agent, an activating agent or a deactivating agent, as defined herein. A matrix is also a medium that may simply provide support, structural integrity or structural barriers. The matrix may be polymeric, non-polymeric, hydrophobic, hydrophilic, lipophilic, amphiphilic, and the like.[0112]
• The matrix of the therapeutic agent layers can be made from pharmaceutically acceptable polymers, such as those typically used in medical devices. The term “polymer” refers to molecules formed from the chemical union of two or more repeating units, called monomers. Accordingly, included within the term “polymer” may be, for example, dimers, trimers and oligomers. The polymer may be synthetic, naturally-occurring or semisynthetic. In preferred form, the term “polymer” refers to molecules which typically have a M[0113]_wgreater than about 3000 and preferably greater than about 10,000 and a M_wthat is less than about 10 million, preferably less than about a million and more preferably less than about 200,000. Examples of polymers include but are not limited to, poly-α-hydroxy acid esters such as, polylactic acid, polyglycolic acid, polylactic-co-glycolic acid, polylactic acid-co-caprolactone; polyethylene glycol and polyethylene oxide; polyvinyl pyrrolidone; polyorthoesters; polysaccharides and polysaccharide derivatives such as polyhyaluronic acid, polyalginic acid, chitin, chitosan, cellulose, hydroxyehtylcellulose, hydroxypropylcellulose, carboxymethylcellulose; polypeptides, and proteins such as polylysine, polyglutamic acid, albumin; polyanhydrides; polyhydroxy alkonoates such as polyhydroxy valerate, polyhydroxy butyrate, and the like, and copolymers thereof. The polymers and copolymers can be prepared by methods well known in the art (see, for example, Rempp and Merril: Polymer Synthesis, 1998, John Wiley and Sons) in or can be used as purchased from Alkermes, in Cambridge, Mass. or Birmingham Polymer Inc., in Birmingham, Ala.
• The preferred co-polymer for use in the present invention are poly(lactide-co-glycolide) (PLGA) polymers. The rate at which the polymer erodes is determined by the selection of the ratio of lactide to glycolide within the copolymer, the molecular weight of each polymer used, and the crystallinity of the polymers used.[0114]
• Bioerodible polymers may also be used to form barrier layers that erode at a rate that can be predetermined base on the composition and that contain no therapeutic agent.[0115]
• Additives in Protective, Barrier, or Therapeutic Layer Formulations[0116]
• Typical additives that may be included in a bioerodible matrix are well known to those skilled in the art (see Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton, Pa., 19th ed., 1995) and include but are not limited to pharmaceutically acceptable excipients, adjuvants, carriers, antioxidants, preservatives, buffers, antacids, emulsifiers, inert fillers, fragrances, thickeners, tackifiers, opacifiers, gelling agents, stabilizers, surfactants, emolliehts, coloring agents, and the like.[0117]
• Typical formulations for therapeutic agents incorporated in these medical devices are well known to those skilled in the art and include but are not limited to solid particle dispersions, encapsulated agent dispersions, and emulsions, suspensions, liposomes or microparticles, wherein said liposome or microparticle comprise a homogeneous or heterogeneous mixture of the therapeutic agent.[0118]
• The term “homogeneously disposed” refers to a component which is mixed uniformly in a matrix in such a manner that the component is macroscopically indistinguishable from the matrix itself. An example of a homogeneously disposed component is a drug formulation such as a microemulsion in which small beads of oil are dispersed uniformly in water.[0119]
• The term “heterogeneously disposed” refers to a component which is mixed non-uniformly into a matrix in such a manner that the component is macroscopically distinguishable from the matrix itself. An example of a heterogeneously disposed component is a simple emulsion in which the beads of oil in the water are large enough to cause a turbidity to the solution and can be seen settling out of solution over time. Heterogeneously disposed compositions also include encapsulated formulations where a component, such as a protective layer, is layered onto or around a therapeutic agent or a therapeutic layer, forming a protective shell.[0120]
• The amount of the drug that is present in the device, and that is required to achieve a therapeutic effect, depends on many factors, such as the minimum necessary dosage of the particular drug, the condition to be treated, the chosen location of the inserted device, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.[0121]
• The appropriate dosage level of the therapeutic agent, for more traditional routes of administration, are known to one skilled in the art. These conventional dosage levels correspond to the upper range of dosage levels for compositions, including a physiologically active substance and traditional penetration enhancer. However, because the delivery of the active substance occurs at the site where the drug is required, dosage levels significantly lower than a conventional dosage level may be used with success. Ultimately, the percentage of therapeutic agent in the composition is determined by the required effective dosage, the therapeutic activity of the particular formulation, and the desired release profile. In general, the active substance will be present in the composition in an amount from about 0.0001% to about 99%, more preferably about 0.01% to about 80% by weight of the total composition depending upon the particular substance employed. However, generally the amount will range from about 0.01% to about 75% by weight of the total composition, with levels of from about 25% to about 75% being preferred.[0122]
• Protective and Barrier Layer Formulations[0123]
• The protective and barrier layers of the present invention are beneficial agents comprised of a bioerodible matrix and optionally contain additional additives, therapeutic agents, activating agents, deactivating agents, and the like. Either a property of the chosen material of the protective or barrier layer, or a chemical embedded in the protective or barrier layer provides protection from deactivating processes or conditions for at least one therapeutic agent. In addition to the polymer materials described above, the protective or barrier layer may also be comprised of pharmaceutically acceptable lipids or lipid derivatives, which are well known in the art and include but are not limited to fatty acids, fatty acid esters, lysolipids, phosphocholines, (Avanti Polar Lipids, Alabaster, Ala.), including 1-alkyl-2-acetoyl-sn-glycero 3-phosphocholines, and 1-alkyl-2-hydroxy-sn-glycero 3-phosphocholines; phosphatidylcholine with both saturated and unsaturated lipids, including dioleoylphosphatidylcholine; dimyristoyl-phosphatidylcholine; dipentadecanoylphosphatidylcholine; dilauroylphosphatidyl-choline; dipalmitoylphosphatidylcholine (DPPC); distearoylphosphatidylcholine (DSPC); and diarachidonylphosphatidylcholine (DAPC); phosphatidyl-ethanolamines, such as dioleoylphosphatidylethanolamine, dipahnitoyl-phosphatidylethanolamine (DPPE) and distearoylphosphatidylefhanolamine (D SPE); phosphatidylserine; phosphatidylglycerols, including distearoylphosphatidylglycerol (DSPG); phosphatidylinositol; sphingolipids such as sphingomyelin; glucolipids; sulfatides; glycosphingolipids; phosphatidic acids, such as dipahmitoylphosphatidic acid (DPPA) and distearoylphosphatidic acid (DSPA); palmitic acid; stearic acid; arachidonic acid; oleic acid; lipids bearing polymers, such as chitin, hyaluronic acid, polyvinylpyrrolidone or polyethylene glycol (PEG), also referred to herein as “pegylated lipids”, with preferred lipids bearing polymers including DPPE-PEG (DPPE-PEG), which refers to the lipid DPPE having a PEG polymer attached thereto, including, for example, DPPE-PEG5000, which refers to DPPE having attached thereto a PEG polymer having a mean average molecular weight of about 5000; lipids bearing sulfonated mono-, di-, oligo- or polysaccharides; cholesterol, cholesterol sulfate and cholesterol hemisuccinate; tocopherol hemisuccinate; lipids with ether and ester-linked fatty acids; polymerized lipids (a wide variety of which are well known in the art); diacetyl phosphate; dicetyl phosphate; stearylamine; cardiolipin; phospholipids with short chain fatty acids of about 6 to about 8 carbons in length; synthetic phospholipids with asymmetric acyl chains, such as, for example, one acyl chain of about 6 carbons and another acyl chain of about 12 carbons; ceramides; non-ionic liposomes including niosomes such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohols, polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fatty acid esters, glycerol polyethylene glycol oxystearate, glycerol polyethylene glycol ricinoleate, ethoxylated soybean sterols, ethoxylated castor oil, polyoxyethylene-polyoxypropylene polymers, and polyoxyethylene fatty acid stearates; sterol aliphatic acid esters including cholesterol sulfate, cholesterol butyrate, cholesterol iso-butyrate, cholesterol palmitate, cholesterol stearate, lanosterol acetate, ergosterol palmitate, and phytosterol n-butyrate; sterol esters of sugar acids including cholesterol glucuronide, lanosterol glucuronide, 7-dehydrocholesterol glucuronide, ergosterol glucuronide, cholesterol gluconate, lanosterol gluconate, and ergosterol gluconate; esters of sugar acids and alcohols including lauryl glucuronide, stearoyl glucuronide, myristoyl glucuronide, lauryl gluconate, myristoyl gluconate, and stearoyl gluconate; esters of sugars and aliphatic acids including sucrose acetate isobutyrate (SAIB), sucrose laurate, fructose laurate, sucrose palritate, sucrose stearate, glucuronic acid, gluconic acid and polyuronic acid; saponins including sarsasapogenin, smilagenin, hederagenin, oleanolic acid, and digitoxigenin; glycerol dilaurate, glycerol trilaurate, glycerol monolaurate, glycerol dipalmitate, glycerol and glycerol esters including glycerol tripalmitate, glycerol monopalmitate, glycerol distearate, glycerol tristearate, glycerol monostearate, glycerol monomyristate, glycerol dimyristate, glycerol trimyristate; long chain alcohols including n-decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, and n-octadecyl alcohol; 1,2-dioleoyl-sn-glycerol; 1,2-dipalmitoyl-sn-3-succinylglycerol; 1,3-dipalmitoyl-2-succinylglycerol; 1-hexadecyl-2-palmitoylglycerophosphoethanolamine and palmitoylhomocysteine, and/or combinations thereof.[0124]
• If desired, a cationic lipid may be used, such as, for example, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP); and 1,2-dioleoyl-3-(4′-trimethylammonio)butanoyl-sn-glycerol (DOTB). If a cationic lipid is employed in the lipid compositions, the molar ratio of cationic lipid to non-cationic lipid may be, for example, from about 1:1000 to about 1:100. Preferably, the molar ratio of cationic lipid to non-cationic lipid may be from about 1:2 to about 1:10, with a ratio of from about 1:1 to about 1:2.5 being preferred. Even more preferably, the molar ratio of cationic lipid to non-cationic lipid may be about 1:1.[0125]
• These lipid materials are well known in the art and can be used as purchased from Avanti, Burnaby, B.C. Canada.[0126]
• The preferred lipids for use in the present invention are phosphatidyl-choline, phosphatidylethanolamine, phosphatidylserine, sphingomyelin as well as synthetic phospholipids such as dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, distearoyl phosphatidyl-glycerol, dipalmitoyl phosphatidylglycerol, dimyristoyl phosphatidylserine, distearoyl phosphatidylserine and dipalmitoyl phosphatidylserine.[0127]
• The rate at which the bioerodible matrix erodes is determined by the choice of lipid, the molecular weight, and the ratio of the chosen materials.[0128]
• The protective or barrier layer can erode by either chemical or physical erosion mechanisms. If the layer erodes by a physical mechanism, the layer is typically a thin film from about 0.1 μm to about 3 μm of a non-polymeric material embedded between two polymeric layers. In this instance, the structural integrity of the protective or barrier layer is maintained by the presence of both of these polymeric layers. When the polymeric material closest to the luminal surface erodes away, the protective or barrier layer breaks apart by the physical forces exerted on it from the remaining polymeric layer. In another embodiment, the protective or barrier layer is eroded by chemical interactions, dissolution in water, hydrolysis, or reaction with enzymes.[0129]
• One function of the protective or barrier layer is to protect one or more therapeutic agents from deactivating or degrading conditions. The protection may come from the properties of the material when, for example, a hydrophobic protective or barrier layer would protect a water sensitive agent from water by resisting the influx of moisture. The protective or barrier layer may also act as a physical barrier. For example, a protective or barrier layer comprised of a hydrogel may allow water to be absorbed by the gel, and allow any agents contained within the gel to diffuse out of the gel into the reaction environment. The hydrogel, however, would prevent enzymes from penetrating the layer, thereby protecting any agents contained within from the enzyme. The term “hydrogel” refers to cross-linked polymeric material in which the liquid component is water. Hydrogels may be prepared by cross-linking certain polymers and lipids disclosed herein.[0130]
• Finally the protective or barrier layer does not have to act as a barrier. The protective or barrier layer may protect a therapeutic agent by releasing an agent, such as an activating agent or a deactivating agent, into the reaction environment prior to the release of the therapeutic agent.[0131]
• A therapeutic agent may be incorporated directly in the protective or barrier layer. The therapeutic agent can be heterogeneously or homogeneously dispersed in the protective or barrier layer. The therapeutic agent can be a drug, or a drug formulated into a microcapsule, niosome, liposome, microbubble, microsphere, or the like. In addition, the protective or barrier layer may contain more than one therapeutic agent. For example, a water sensitive drugs, such as a limus, or any other drug that must be administered through intravenous, intramuscular, or subcutaneously, could be incorporated in a hydrophobic matrix such as SAIB, or fatty acid ester.[0132]
• A therapeutic agent may also be disposed in a therapeutic agent layer, separate from the protective or barrier layer. In this case the protective or barrier layer may be adjacent to the therapeutic agent layer and may serve to prevent or retard processes that would degrade or deactivate the therapeutic agent until the protective or barrier layer has substantially eroded. In this instance the protective or barrier layer is a barrier between a therapeutic layer and the reaction environment. This barrier may be a hydrophobic barrier that resists water absorption. The hydrophobic barrier would be used in conjunction with water-sensitive drugs as described above. Alternatively, the protective or barrier layer maybe a hydrogel that resists the absorbance of enzymes. An enzyme resistant barrier would used to protect an drug such as a DNA, RNA, peptide or protein based therapeutic agent.[0133]
• The protective or barrier layer may optionally include activating and deactivating agents for the purpose of preparing the reaction environment for the subsequent release of a therapeutic agent. These activating and deactivating agents are well known to those skilled in the art and include but are not limited to antacids, buffers, enzyme inhibitors, hydrophobic additives, and adjuvants. For example, Mg(OH)[0134]₂in particles of about 0.5 μm to about 5 μm more preferably, about 1 μm incorporated in a PLGA polymer layer could be used in conjunction with any acid senstive drug. An example of an activating agent is chymotrypsin, which may be incorporated in polyvinyl pyrrolidone layer. The chymotrypsin, could be used to convert a pro-drug to an active drug.
• While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.[0135]

Claims (29)

We claim:

1. A device for the controlled release of one or more drugs comprising:

an implantable stent;

at least two reservoirs in the stent; and

a release system contained in each of the at least two reservoirs, wherein the release system comprises one or more drugs for release.

2. The device ofclaim 1, where the release system provides continuous release of the one or more drugs from the at least two reservoirs.

3. The device ofclaim 1, wherein the release system provides pulsatile release of the one or more drugs from the at least two reservoirs.

4. The device ofclaim 1, wherein the release system comprises drug molecules in a matrix formed of a degradable material.

5. The device ofclaim 1, wherein the drug is homogeneously distributed within the release system.

6. The device ofclaim 1, wherein the drug is heterogeneously distributed within the release system.

7. The device ofclaim 1, wherein the reservoirs contains two or more layers, at least one of which comprises the release system.

8. The device ofclaim 1, wherein the release system further comprises a synthetic biodegradable polymer.

9. The device ofclaim 8, wherein the synthetic biodegradable polymer is selected from the group consisting of polyanhydrides and polyorthoesters.

10. The device ofclaim 1, wherein the release system further comprises a bioerodible hydrogel.

11. The device ofclaim 1, wherein the one or more drugs are in the form of a solid or gel.

12. The device ofclaim 1, wherein the release system further comprises at least one excipient.

13. The device ofclaim 1, wherein the at least two reservoirs are each covered by a reservoir cap.

14. The device ofclaim 13, wherein the drug is released from the reservoirs by passive means.

15. The device ofclaim 14, wherein the reservoir cap is formed of a material that degrades or dissolves over time.

16. The device ofclaim 13, wherein the reservoir cap comprises a polymeric material.

17. The device ofclaim 14, wherein at least one reservoir cap is formed of a first material and at least one other reservoir cap is formed of a second material, wherein the first material has a different degradation rate, a different dissolution rate, or a different permeability to the drug molecules compared to the second material.

18. The device ofclaim 13, wherein the drug is released from the reservoirs by active means for disintegrating or rupturing the reservoir cap.

19. The device ofclaim 1, wherein a first drug is in at least one of the reservoirs and a second drug is in at least one other of the reservoirs, the first drug and the second drug being different in kind or dose.

20. The device ofclaim 1, wherein the one or more drugs comprise a protein, a polysaccharide, or a nucleic acid.

21. The device ofclaim 1, wherein the one or more drugs comprise an anesthetic.

22. The device ofclaim 1, wherein the one or more drugs comprise an antibiotic.

23. The device ofclaim 1, wherein the one or more drugs comprise an anti-inflammatory agent.

24. The device ofclaim 1, wherein the one or more drugs comprise an anti-hypertensive agent.

25. The device ofclaim 1, wherein the one or more drugs comprise a chemotherapeutic agent.

26. The device ofclaim 1, wherein the one or more drugs comprise a hormone.

27. The device ofclaim 1, wherein the one or more drugs comprise an immunomodulator.

28. The device ofclaim 1, wherein the implantable stent is an arterial or vascular stent.

29. The device ofclaim 1, wherein the implantable stent comprises a metal.

Images